Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Joost L. Boormans et al.|The Lancet Oncology|2021Cited by 532
Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational StudyMaximilian Pallauf, Benjamin Pradère, David D‘Andrea et al.|The Journal of Urology|2022Cited by 24